Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…

Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.

Renal-cell carcinoma

Oncology and palliative care · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Major haematuria or venous complication

Clot retention, severe anaemia, pulmonary embolism or haemodynamic bleeding can complicate a vascular renal tumour or caval thrombus.

Action: Resuscitate, correct obstruction with urgent urology, obtain contrast imaging when feasible and involve interventional radiology, vascular and renal cancer teams for embolisation, thrombectomy or surgery according to the cause.

Synopsis

Characterise renal masses without unnecessary biopsy, identify venous extension and metastatic symptoms, preserve renal function through risk-adapted surgery or surveillance and sequence immune and targeted treatment for advanced disease.

  • Incidental renal mass is a pivotal clue in Renal-cell carcinoma: Many localised tumours are found on imaging for another reason and require dedicated characterisation rather than immediate radical nephrectomy.
  • Immediate priority in unstable Renal-cell carcinoma: Resuscitate, correct obstruction with urgent urology, obtain contrast imaging when feasible and involve interventional radiology, vascular and renal cancer teams for embolisation, thrombectomy or surgery according to the cause.
  • Renal-protocol multiphase CT is used early to characterise enhancement, anatomy, local invasion, renal vein and IVC extension and the contralateral kidney. A solid enhancing cortical mass is suspicious; enhancement pattern suggests but does not prove subtype, and complex cysts require Bosniak classification.
  • MRI renal and venous assessment refines the next decision because use when CT is inconclusive or venous anatomy affects surgery; avoid treating bland and tumour thrombus as interchangeable.
  • Define mass, kidney and spread: Obtain renal-protocol multiphase imaging and assess size, complexity, nodes, renal vein or IVC extension and contralateral renal reserve.
  • Preserve nephrons without losing control: Use radical nephrectomy for tumours not safely amenable to nephron-sparing surgery, planning IVC thrombectomy in a specialist centre when needed.
  • A major avoidable harm is venous tumour thrombus; Extension into the IVC can cause embolic symptoms, hepatic outflow problems and complex surgery requiring vascular and cardiothoracic planning.
  • A common diagnostic trap is oncocytoma: A benign enhancing renal neoplasm can mimic RCC on imaging; biopsy may help when surveillance or ablation is considered.

Key red flags

Visible haematuria, flank pain or a palpable mass warrants urgent urinary-tract assessment, although the full triad is late.

Clot retention, symptomatic anaemia or haemodynamic bleeding requires immediate urological care.

New varicocele that persists supine, leg oedema or venous thrombosis may reflect renal-vein or IVC tumour extension.

Unexplained bone pain, cough, weight loss, hypercalcaemia or neurological symptoms suggests metastatic disease.

A renal mass appears in a young patient or is bilateral, multifocal or associated with a syndromic family history.

Acute bleeding

Clot retention, falling haemoglobin or shock from urinary or retroperitoneal bleeding requires emergency escalation.

Investigation priorities

01
Renal-protocol multiphase CTFirst step

Characterise enhancement, anatomy, local invasion, renal vein and IVC extension and the contralateral kidney.

Management branches

CharacteriseDefine mass, kidney and spread

Imaging identifies a solid or complex cystic renal mass.

  1. Obtain renal-protocol multiphase imaging and assess size, complexity, nodes, renal vein or IVC extension and contralateral renal reserve.
  2. Stage the chest and investigate bone, brain or other sites when tumour risk or symptoms warrant it.
  3. Use core biopsy before ablation or systemic treatment and when histology will resolve surveillance versus intervention; offer genetics review for hereditary features.

Key medicines

Pembrolizumab with axitinibUse pembrolizumab 200 mg IV every 3 weeks or 400 mg every 6 weeks with axitinib 5 mg orally twice daily, with axitinib interruption, reduction or escalation according to the specialist protocol.Monitor immune toxicity, blood pressure, urine protein, thyroid, renal and liver function, diarrhoea, hand–foot symptoms, bleeding, thrombosis and wound healing; pause axitinib around major surgery.
Nivolumab with ipilimumabGive nivolumab 3 mg/kg plus ipilimumab 1 mg/kg IV every 3 weeks for 4 doses, then nivolumab maintenance using a licensed flat-dose schedule such as 240 mg every 2 weeks or 480 mg every 4 weeks.Combination therapy increases serious immune hepatitis, colitis, pneumonitis, endocrinopathy, nephritis, myocarditis and neurological toxicity; baseline and symptom-triggered organ assessment must be rapid.
Open full textbook →Answer 2 questions
Sources and review status4 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • European Association of Urology renal cell carcinoma guidelineCurrent professional guidance used in UK specialist practice for renal cell carcinoma.
  • Royal College of Pathologists cancer datasetsUK pathology sampling, staging, margin and molecular reporting standards.
  • NICE NG12 suspected renal and urological cancer referralCurrent NICE recommendations for suspected renal and urological cancer referral assessment and treatment.
  • BNF pembrolizumab, axitinib, nivolumab and ipilimumabUK prescribing, contraindication and monitoring information for pembrolizumab, axitinib, nivolumab and ipilimumab.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom